ajmore Posted - 1 day ago

$VALN the $SNY $NVAX deal should be a clear indicator that large pharma want to take over the sub billion companies and their products. Valneva taken over by large pharma, $PFE $BAYRY or even $SNY is getting quite closer. Buy! target 12 Eur for European line, 26 USD for ADR

ajmore Posted - 2 days ago

$VALN now Simply Wall Street, gone bullish!

XBI2022 Posted - 4 days ago

$VALN

XBI2022 Posted - 4 days ago

$VALN Q1 revenues came in at € 32.8 m. Analysts expected sales of € 66.6 m, acc. to Business Insider.

ajmore Posted - 4 days ago

$VALN target 12 for the European line. 25 usd for ADR.

ajmore Posted - 4 days ago

$VALN grab your shares while the ugly European market makers try to prevent it from rallying. They will have to close their massive hidden short. target 12

ajmore Posted - 4 days ago

$VALN absolute bargain!

Boonkers Posted - 4 days ago

$VALN https://valneva.com/press-release/valneva-reports-first-quarter-2024-financial-results-and-provides-corporate-updates/

ajmore Posted - 1 week ago

$VALN excerpts from the presentation:

ajmore Posted - 1 week ago

$VALN valneva presentation is extremely positive. Company shows RSV vaccine added to the pipeline, company looking for partner. Expect the announcement soon!

baerenmarkt Posted - 04/30/24

$VALN Is today the Chikugunya vax approval day or a few days later? How far will Valn jump?

ajmore Posted - 04/18/24

$VALN usual momentum short sellers, most likely marshall wace and Qube, failed to bring it down. More buyers on board! announcement is imminent. Buy target 10 Eur (21 ADR).

Night_Owl_Biotech Posted - 04/14/24

Attached (left) = all acquisitions of comm'l-stage non-oncology biopharmas acquired since 1/1/17. It's our non-professional experience most new therapies are acquired within 1 to 2 years post approval. We do not recall many acquisitions of comm'l-stage bios w/approvals post 3 years (pls lets us know if we are missing any). (Right) = all non-oncology bios with a FDA approval over the last 4 years (market cap $100MM+). If we had to guess (for entertainment), we suspect $VALN would be acquired sooner rather than later since Pfizer already owns a good piece of VALN & VALN's new vaccine should be a good fit. VALN cash includes $103MM from the sale of PRV. Takeda sells Vonoprazan in Japan making $PHAT an obvious candidate. $TARS is 1 of the best performers in biopharma the last 12 months (excl. recent financing). Next step is a B/O (a guess). Last, watch $URGN as Friday's trading was highly unusual. B/O candidate? This is not investment advice. Be careful, our data may be wrong too.

Boonkers Posted - 04/12/24

$VALN UP ALMOST 5% IN EUROPE

Kendo999 Posted - 1 month ago

$VALN This was an interview with Thomas Lingelbach (Valneva CEO) for the AKTIONAER investing magazine on 3rd April 2024. https://www.deraktionaer.de/artikel/pharma-biotech/valneva-ceo-lingelbach-im-aktionaer-gespraech-in-einer-komfortablen-finanziellen-situation-20354226.html . It's a Google translation so it won't be perfect.

Boonkers Posted - 1 month ago

$VALN Regarding EMA approval, if any more data was required then they would have requested it months ago. Due to the fact that the FDA has already approved + recommended, Valneva’s data is surely very solid.

Kendo999 Posted - 1 month ago

$VALN EMA Approval for Chikungunya before months end. Accelerated assessment started on 27 Nov 2023 and takes 150 days. Contracts for US & US military can come in any time now.

TheCheeseWrangler Posted - 03/26/24

$VALN https://valneva.com/press-release/valneva-initiates-phase-1-trial-of-second-generation-zika-vaccine-candidate/

ajmore Posted - 03/25/24

$VALN Something is cooking! checkout the volume traded today in the European lines... come on, Pfizer, $PFE we know you got your eyes on Valneva.

Thestocktraderhubzee Posted - 03/25/24

WATCHLIST MAR 25 2024. $SRAD Citigroup Maintains Buy on Sportradar Gr, Raises Price Target to $17 $VALN Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17 $MREO Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target $DESP Cantor Fitzgerald Reiterates Overweight on Despegar.com, Maintains $14 Price Target $HQY Keybanc Maintains Overweight on HealthEquity, Raises Price Target to $95

Thestocktraderhubzee Posted - 03/22/24

$VALN Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17

ajmore Posted - 03/22/24

$VALN imho forward pe is 2! in a year, time forward, pe is 1! (ixiaro, lyme, travel will bring in 550 mln from 2026 with most profit). Shares will be scooped up, especially since hedge funds will be covering since there is no worry about any debt payment issues! Buy target EUR 15 (ADR usd 32).

Boonkers Posted - 03/21/24

$VALN https://valneva.com/press-release/valneva-to-present-on-its-chikungunya-vaccine-ixchiq-participate-in-multiple-events-at-the-24th-world-vaccine-congress-in-washington-d-c/

XBI2022 Posted - 03/20/24

$VALN Die Anleger haben sich offensichtlich mehr von Valneva erhofft. Die ersten Analysten haben indes bereits ihre positive Einschätzung bestätigt: Kempen rät weiter zum Kauf mit einem Zielkurs von 10 Euro, Oddo BHF sieht den Impfstoff-Titel sogar erst bei 12 Euro fair bewertet. DER AKTIONÄR findet den Wert ebenfalls mittel- bis langfristig interessant.

Boonkers Posted - 03/20/24

$VALN WTF, IT GOES TO €4,10 THEN BOMBS ALL THE WAY TO €3,35 AND COUNTING. WHAT A SWING TRADE THIS COULD HAVE BEEN. EARNINGS WERE SOLID.

Boonkers Posted - 03/20/24

$VALN https://valneva.com/press-release/valneva-reports-full-year-2023-results-and-provides-business-updates-and-outlook/

Boonkers Posted - 03/18/24

$VALN https://valneva.com/press-release/valneva-announces-extension-of-the-interest-only-period-of-its-debt-facility-with-deerfield-and-orbimed/

Bogings Posted - 03/16/24

$VALN valn’s revenu streem iz groein’ . chikun vax iz on mkt, apprvls brewin in var e us mkts. tyme wil pruuve ths owt.

Jhony_rose Posted - 03/15/24

$VALN the Stock is dead

Jhony_rose Posted - 03/12/24

$VALN